EP0805680A2 - Zusammensetzungen zur behandlung von migräna und andere krankheiten, welche sesquiterpene lactone und vitamin b complexe enthalten - Google Patents

Zusammensetzungen zur behandlung von migräna und andere krankheiten, welche sesquiterpene lactone und vitamin b complexe enthalten

Info

Publication number
EP0805680A2
EP0805680A2 EP96900799A EP96900799A EP0805680A2 EP 0805680 A2 EP0805680 A2 EP 0805680A2 EP 96900799 A EP96900799 A EP 96900799A EP 96900799 A EP96900799 A EP 96900799A EP 0805680 A2 EP0805680 A2 EP 0805680A2
Authority
EP
European Patent Office
Prior art keywords
composition
sesquiterpene lactone
riboflavin
complex vitamin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96900799A
Other languages
English (en)
French (fr)
Inventor
Natalie J. Lazarowych
Peter Pekos
Michael O'connell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ashbury Research Corp
Original Assignee
Ashbury Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ashbury Research Corp filed Critical Ashbury Research Corp
Publication of EP0805680A2 publication Critical patent/EP0805680A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to compositions and methods useful in the treatment of migraine headaches and related illnesses.
  • migraine migraine including cluster headaches
  • Treatment for many patients having the occasional migraine involves simple analgesics with or without sedatives. Approximately 10% of migraine sufferers have three or more attacks per month and warrant prophylactic treatment. Twenty-five to fifty percent of this group benefit from treatment with beta-adrenoreceptor blocking agents, clonidine or, in the female sufferer, gestagen hormones.
  • beta-adrenoreceptor blocking agents clonidine
  • Feverfew rich in sesquiterpene lactones, principally parthenolide
  • sixty-eight percent of migraine sufferers displayed improvement when treated prophylactically with riboflavin.
  • Non-selective antagonist drugs will, therefore, not only reduce the smooth muscular spasm (of intracranial blood vessels in the case of migraine, or bronchial smooth muscle in the case of asthma) but also the pain
  • Sesquiterpene lactones are known to be present in many plants, for example in Asteracea, Magnoliaceae, and in particular in Tanacetum parthenium
  • a sesquiterpene lactone or a source of sesquiterpene lactones, such as sesquiterpene lactone-containing plants and plant extracts, is used in combination with a B-complex vitamin, such as riboflavin.
  • Preparations comprising such a combination are also provided that have pharmaceutical use, particularly in the treatment of migraine, including cluster, headaches and various arthritic and bronchial conditions, such as asthma.
  • the B-complex vitamin that is useful in accordance with the present invention includes riboflavin, riboflavin phosphate, flavin adenine dinucleotide, nicotinic acid, folic acid, cyanocobalmin, para-amino benzoic acid, thiamine, py ⁇ ' doxine, pantothenic acid, biotin, choline inositol, and carnitine.
  • the sesquiterpene lactone that is useful in accordance with the present invention includes germacranolides, guaianolides, and pseudoguaianolides, in particular those sesquiterpene lactones having an ⁇ -methylene substituent in the lactone ring, such as parthenolide.
  • Parthenolide and sesquiterpene lactone- containing plant materials, such as feverfew leaf or extracts from such plant materials are preferred.
  • These natural-sources of actives are preferred because they deliver many active components, not only a single chemical entity.
  • the variety of active components and active chemical species present results in preparations with a broader spectrum of activity compared to pure sesquterpine lactones.
  • both sesquiterpene lactones and B-complex vitamins have been found, individually, to be effective for treatment or prophylaxis of migraine
  • the combination of the two types of actives leads to synergistic effects.
  • a combination of feverfew or other source of parthenolide with a B-vitamin additive leads to a further decrease in the frequency of the attacks and causes the attacks to be less painful.
  • An increased percentage of migraine sufferers should therefore display an improvement in frequency, severity, or both, when treated prophylactically with the combinational drug.
  • the combinational drug has low toxicity, surprisingly few side-effects and may be taken for the extended periods required for effective prophylaxis, without adverse reactions.
  • the dosage of active ingredients will, of course, vary from individual to individual and will depend upon many factors, including body weight, metabolism, and the like. In general, however, it is believed that, in both treatment and prophylaxis, a given individual should receive from about 50 to about 10,000 micrograms, preferably from about 250 to about 1000 micrograms, and most preferably about 250 micrograms of sesquiterpene lactone, such as parthenolide, per day. In general, it is also believed that a given individual should receive from about 0.1 to about 5,000 milligrams, preferably from about 100 to about 500 milligrams, and most preferably about 400 milligrams of B- complex vitamin, especially riboflavin, per day. More, however, may be need in the case of acute attacks.
  • pharmaceutical dosage forms contain from about 50 to about 10,000 micrograms, preferably from about 250 to about 1000 micrograms, and most preferably about 250 micrograms of sesquiterpene lactone, such as parthenolide, in combination with about 0.1 to about 5,000 milligrams, preferably from about 100 to about 500 milligrams, and most preferably about 400 milligrams of B-complex vitamin, especially riboflavin, per day.
  • such pharmaceutical dosage forms may comprise from about 5 to 300 mg, especially 50 to 200 mg, of feverfew leaf, containing about 250 micrograms of parthenolide, in combination with from about 0.1 to 400 mg of riboflavin per day.
  • the feverfew dosage may be adjusted to accommodate the naturally variable levels of sesquiterpene lactones, such as parthenolide.
  • a particularly preferred capsule contains about 125 mg of high-parthenolide feverfew and 400 mg of riboflavin.
  • composition of the present invention be administered as two tablets daily; each tablet containing 125 mg feverfew (containing 250 mg of sesquiterpene lactone) and 200 mg riboflavin or other B-complex vitamin.
  • the combination of actives may also be administered by independent dosage forms. For example, two tablets of feverfew, each containing 250 ⁇ grams of parthenolide may be taken daily in addition to two tablets of B complex vitamin, each containing 200 mgrams of riboflavin.
  • the preparations may be administered orally, or parenterally and conveniently take the form of a tablet, caplet, capsule, lozenge, injectable solution, liquid suspension or elixir. Circumstances may arise wherein the dose is best administered by suppository, inhalation, slow release implant, slow release patch or other topical vehicle.
  • the combination of active ingredients are usually best given in an oral form made up as a tablet, caplet, capsule, or as a liquid suspension or elixir one or two times daily.
  • oral administration the preparation may be admixed with any conventional tableting or capsuling carrier, or as a suspension or solution in any orally acceptable non-toxic liquid carrier.
  • the drug may be provided in encapsulated form for sustained release over a period of time.
  • parenteral administration the drug may be provided as a suspension or solution in any suitable, sterile injection medium, e.g. sterile aqueous saline solution
  • the pharmaceutical formulations may additionally include, in addition to the aforementioned active agents, other known anti-migraine preparations, sedatives and relaxants, analgesics and antiemetics such as:
  • Excellent efficacy of a preparation in accordance with this invention is likely in all forms of migraine including the treatment of classical and common migraine, migrainous neuralgia (cluster headache), and premenstrual and menstrual migraine and other headaches.
  • compositions of the present invention may be used in the prevention of the aforementioned types of headache by reducing the frequency, severity and duration of the attacks and by reducing the nausea and vomiting symptoms.
  • the compositions may also be used to treat acute attacks of the aforementioned types of headache, by reducing their duration, severity and the intensity of associated symptoms.
  • preparations in accordance with the invention may be administered orally, or parenterally and conveniently take the form of a tablet, capsule, injectable, liquid suspension or elixir. Circumstances may arise where it is best administered by suppository, inhalation, slow release implant, slow release patch, or other topical vehicle. Dosage and administration are as indicated above.
  • a preparation in accordance with the invention may additionally include other anti-arthritis agents including non-steroidal anti-inflammatory drugs, analgesics, skeletal muscle relaxants, steroids, gold and penicillamine.
  • agents examples include aspirin, indomethacin, piroxicam, benorylate, ibuprofen, paracetamol, salicylamine, diflunizal, ethoheptazine, fenoprofen (calcium fenoprofate) flufenamic acid, mefenamic acid, naproxen sodium, ketoprofen, phenylbutazone, sulindac, penicillamine, salicylate, fenclofenac, flurbiprofen, fenbufen, feprazone, sodium aurothiomalate, naproxen, benoxaprofen, aloxipria, hydroxychloroquine sulphate, azapropazone, tolemtin, choline magnesium trisalicylate, diclofenac, adrenal steroids such as prednisone or prednisolone, white willowbark and its extracts, other non-steroidal anti-inflammatory agents of
  • compositions of the present invention may be used in the treatment of rheumatoid arthritis, osteoarthritis, arthritis associated with Felty's syndrome,
  • Still's disease systemic lupus erythematosus, polyarteritis nodosa, scleroderma, gout, achalasia of the cardia, Crohn's disease, chronic brucellosis, ankylosing spondylitis, sarcoidosis, psoriasis and gonorrhoea.
  • the preparations are believed to be useful in the prevention of the above arthritides, being effective in reducing the frequency, severity and duration of the symptoms.
  • the preparations can also be used to treat the acute attacks of the above arthritides reducing their duration, severity and associated symptoms.
  • compositions of the present invention can be enhanced by the presence of gamma linoleic acid.
  • the compositions may comprise, in addition to a sesquiterpene lactone and a B- complex vitamin, gamma linoleic acid or a source thereof.
  • the linoleic acid source may be, for example, evening primrose oil or borage oil.
  • preparations in accordance with the invention may be administered orally, or parenterally and conveniently take the form of a tablet, capsule, injectable, liquid suspension or elixir. Circumstances may arise where it is best administered by suppository, inhalation, slow release implant, slow release patch or other topical vehicle. Dosage and administration are as indicated above.
  • a preparation in accordance with the invention may be co-administered with or additionally include other ingredients such as bronchodilator, antihistamine and anti-infective agents, examples of which agents are: isoprenaline sulphate, orciprenaline, adrenaline, terbutaline sulphate, theophylline, brazilian cocoa choline theophyllinate, aminophylline, ephedrine hydrochloride, papaverine hydrochloride, ipratropium bromide, atropine methonitrate, beclomethasone dipropionate, fenoterol hydrobromide, betamethasone, isoetharine mesylate or hydrochloride, phenylephrine hydrochloride or bitartrate, thenyldiamine hydrochloride, reproterol hydrochloride, deptropine citrate, butethamate citrate, acepifylline, diphenylpyraline hydrochloride, sodium
  • H1 -receptor antagonists diprophylline, methoxyphenamine hydrochloride, rimiterol hydrobromide, hyoscine hydrobromide, salbutamol sulphate, ketotifen hydrogen fumarate, pseudo-ephedrine hydrochloride, bromhexine hydrochloride, and antifungal, antibacterial and antiviral agents.
  • the composition in accordance with the present invention is believed to be useful in the treatment of bronchial asthma, bronchoconstriction associated with chronic bronchitis, and symptoms associated with histamine release in allergic hypersensitivity phenomena such as hay fever and anaphylaxis.
  • Compositions in accordance with the invention will now be illustrated in more detail with reference to the following Examples:
  • Powdered feverfew leaf and riboflavin are mixed in the following proportions:
  • the mixture is encapsulated into a soft shell capsule or hard shell capsule or two piece hard shell gelatin capsules.
  • the capsules may be treated to retard disintegration or absorption by the use of gastro-resistant coatings, such as hydroxymethyl propyl cellulose, or the content may be mixed with polymeric matrix materials as those known to the pharmaceutical industry, to release the active ingredients at a controlled rate.
  • gastro-resistant coatings such as hydroxymethyl propyl cellulose
  • the soft shell or two piece hard shell gelatin capsule may be used via the oral or rectal route.
  • the pH is adjusted to between 2 and 6.5, using HCI.
  • the injectable may be administered by intramuscular, subcutaneous, or intravenous injection.
  • the preparation should be stored in tight, light-resistant containers, preferably between 15-25° C.
  • Caplets may be enteric coated, sugar coated, film coated or prepared as a laminated tablet.
  • the dry solids are triturated and the purified water is slowly added with trituration.
  • the pH is adjusted to between 3 and 6.5 using HCI as required.
  • the suspension may be administered by ingestion.
  • the preparation should be stored in tight, light-resistant containers, preferably between 15-25°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
EP96900799A 1995-01-26 1996-01-25 Zusammensetzungen zur behandlung von migräna und andere krankheiten, welche sesquiterpene lactone und vitamin b complexe enthalten Withdrawn EP0805680A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002141126A CA2141126A1 (en) 1995-01-26 1995-01-26 Combinational drug for treating migraine and other illnesses
CA2141126 1995-01-26
PCT/CA1996/000052 WO1996022774A2 (en) 1995-01-26 1996-01-25 Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins

Publications (1)

Publication Number Publication Date
EP0805680A2 true EP0805680A2 (de) 1997-11-12

Family

ID=4155120

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96900799A Withdrawn EP0805680A2 (de) 1995-01-26 1996-01-25 Zusammensetzungen zur behandlung von migräna und andere krankheiten, welche sesquiterpene lactone und vitamin b complexe enthalten

Country Status (6)

Country Link
EP (1) EP0805680A2 (de)
JP (1) JPH10512573A (de)
KR (1) KR19980701720A (de)
AU (1) AU4478096A (de)
CA (1) CA2141126A1 (de)
WO (1) WO1996022774A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957928A1 (de) * 1997-03-03 1999-11-24 Laboratoires Remilea Pflanzenextrakte zubereitungen, verfahren zu deren herstellung und diese extrakte enthaltende pharmazeutische zusammensetzung
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6068999A (en) 1998-06-25 2000-05-30 Hendrix; Curt Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
DE19844836A1 (de) * 1998-09-30 2000-04-20 Hexal Ag Pharmazeutisch, wirksames, pflanzliches Präparat zur Behandlung von Migräne
DK0951842T3 (da) 1999-01-20 2003-01-06 Nutricia Nv Ernæringsprodukt til et spædbarn
US6312736B1 (en) * 1999-12-09 2001-11-06 Biotech Corporation Herbal composition to relieve pain
CA2406733A1 (en) * 1999-12-23 2001-06-28 Harikrishna Nakshatri Use of parthenolide to inhibit cancer
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7192614B2 (en) * 2002-11-05 2007-03-20 Gelstat Corporation Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
US20040247705A1 (en) * 2003-06-06 2004-12-09 Roberts Stephen C. Transdermal compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
WO2008010335A1 (fr) * 2006-07-21 2008-01-24 Mmt Co., Ltd. Extrait végétal ayant un effet préventif sur l'arthrite
WO2008075649A1 (ja) * 2006-12-20 2008-06-26 Mmt Co., Ltd. 発毛促進用飲食物、医薬部外品、医薬組成物ならびに発毛促進方法
WO2008075466A1 (ja) * 2006-12-20 2008-06-26 Mmt Co., Ltd. 発毛促進用飲食物、医薬部外品、医薬組成物ならびに発毛促進方法
CN101278928B (zh) 2007-04-06 2011-09-07 常州高新技术产业开发区三维工业技术研究所有限公司 含左卡尼汀或其衍生物的药物组合物及其用途
US20100284986A1 (en) * 2009-05-06 2010-11-11 Kelleher Kevin J Compositions and methods for prevention and treatment of migraines
IT201700085185A1 (it) * 2017-07-26 2019-01-26 Cristalfarma S R L Integratore alimentare per uso come coadiuvante nel trattamento e profilassi dell’emicrania

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4173M (de) * 1965-02-01 1966-05-23
CA1270843A (en) * 1982-05-19 1990-06-26 Edward Stewart Johnson Sesquiterpene lactones
US4542026A (en) * 1983-04-29 1985-09-17 Jose Rios Method of treating vasomotor disorders
JPS63303915A (ja) * 1987-06-05 1988-12-12 Nikko Sogyo Kk 養毛用組成物
DE3808141A1 (de) * 1988-03-11 1989-09-21 Mai Jutta Mittel zur bekaempfung von migraene
JPH0713021B2 (ja) * 1991-08-01 1995-02-15 文夫 堂園 消化器系疾患治療用内服薬剤
JPH05306231A (ja) * 1992-04-24 1993-11-19 Pola Chem Ind Inc 皮膚外用剤
WO1994001899A1 (en) * 1992-07-02 1994-01-20 W. L. Gore & Associates, Inc. Sealing frame and protective membrane for a radar dish or horn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9622774A2 *

Also Published As

Publication number Publication date
JPH10512573A (ja) 1998-12-02
WO1996022774A3 (en) 1996-09-26
WO1996022774A2 (en) 1996-08-01
KR19980701720A (ko) 1998-06-25
AU4478096A (en) 1996-08-14
CA2141126A1 (en) 1996-07-27

Similar Documents

Publication Publication Date Title
US4758433A (en) Oil extract of Tanacetum parthenium for treating migraine
EP0805680A2 (de) Zusammensetzungen zur behandlung von migräna und andere krankheiten, welche sesquiterpene lactone und vitamin b complexe enthalten
TW389696B (en) Accelerated release composition containing bromocriptine
JP2002518456A (ja) 脳血管の正常状態を支持するための栄養補助食品
WO2006099274A1 (en) Dietary supplement and method of using same
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
JP3018160B2 (ja) 月経困難症及び／又は月経前症候群の軽減用薬剤
JP2008501655A (ja) メロキシカム含有組成物
EA002166B1 (ru) Фармацевтическая композиция, содержащая трамадол - лекарственное средство для лечения мигрени
CZ289395A3 (en) Transdermic therapeutic system for administration of serotonin agonists
US5082665A (en) Anti-snoring formulations using yohimbine
JP2001518481A (ja) 経口投与のためのセロトニン含有製剤及びその使用方法
US4794112A (en) Acetaminophen/hydroxyzine analgesic combinations
WO2005084392A2 (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
US5011841A (en) Treatment of depression
US5026706A (en) Method for treating dysuria using naftopidil
Sjaastad et al. 2‐(2.6‐dichlorophenylamino)‐2‐imidazoline hydrochloride (ST 155 or Catapresan) as a prophylactic remedy against migraine
GB2248392A (en) Composition to combat alcoholism
JP2001097856A (ja) 鎮咳剤
US20110117070A1 (en) Compositions and methods for treating headache
US4515802A (en) Analgesic preparations
Beaumont Clomipramine (Anafranil) in the treatment of pain, enuresis and anorexia nervosa
AU2775500A (en) Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and B-complex vitamins
JPH04173741A (ja) 高血圧症予防・治療剤
JPS60500016A (ja) 鎮痛薬組成物類

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970822

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000821

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010301